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INTRODUCTION
Generally, diabetic nephropathy (ICD-
10 (2014)= E11.22) could develop in about
30% of type 2 diabetic patients (ICD-10
(2014)= E11) in different communities.1
After several weeks of initiation of diabetes,
glomerular filtration rate increases due to
glomerular hyperfiltration (GFR). Later,
after 5-10 years microalbuminuria (urine
albumin 30 to 300 mg/day) may develop in
some patients. In untreated patients,
macroalbuminuria (urine albumin ≥ 300
mg/day) usually occurs during 5 to 10 years.
At the beginning of macroalbuminuria, GFR
may decrease gradually at the rate of 1
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ABSTRACT
Background and aims: Diabetic nephropathy (DN) is the most common cause of end-
stage renal failure which could increase the risk of cardiovascular disease and morbidity
and mortality in patients. The aim of this study was to investigate new modalities for
treatment of diabetic nephropathy.
Methods: This study was a mini-review research to investigate drugs that are used for
DN treatment.
Results: Angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptors
blocker (ARB) are the bases of DN treatment during recent decades. Due to some of
adverse reactions of these drugs like hyperkalemia and chronic cough, other drugs such
as non dihydropridin Ca channel blockers, uric acid lowering drugs, renin antagonists,
lipid lowering agents, oral hypoglycemic agents such as Thiazolidinediones, Vitamin D
and selective endothelin receptor antagonists have been used in some studies for
decreasing proteinuria and slowing progression of DN. The results of these studies are
different and controversial in some cases.
Conclusion: The cornerstone of diabetic nephropathy is prescription of angiotensin
receptor antagonists or angiotensin converting enzyme inhibitors or combination of two
classes of drugs. For increasing the antiproteinuric effect of treatment or occurring the
adverse effects of these drugs, (especially hyperkalemia), other agents such as Ca channel
blockers, direct renin inhibitors, thioglithazons, uric acid lowering drugs or vitamin D
may be added or replaced.
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ml/month or 10-12 ml/year, so almost in all
of untreated patients, the end-stage renal
disease (ESRD) could develop after the
additional 5-10 years.2
Diabetic nephropathy (DN) is the most
common cause of end-stage renal failure in
many countries and it is the cause of
increasing risk of cardiovascular disease. In
patients with DN, urine sediment is usually
inactive (bland), but microscopic hematuria
can occur in some patients especially in
cases of other glomerulopathies.3 Moreover,
severity of proteinuria is variable. So, some
patients may suffer from severe nephrotic
syndrome up to 20 gr/day.4 In addition,
treatment in micro- albuminuric phase may
prevent development of nephropathy;
however, in macro albuminuric phase,
proper management may just make the
progression of ESRD slow or decrease the
cardiovascular mortality.5
Management of DN may include
lifestyle modifications (regular exercise,
weight loss in obese patients, restriction of
dietary protein intake, limitation of salt and
alcohol intake), smoking cessation, blood
pressure controlling and adequate blood
glucose controlling (glycosylated
hemoglobin<7 percent). Moreover, blood
pressure controlling is the other important
modality of DN management. Inhibition of
the renin–angiotensin aldosterone system
with ACE inhibitors or angiotensin II–
receptor blockers can also decrease both the
blood pressure and proteinuria. Goal of
blood pressure management in DN patients
is a systolic pressure below 130 mm Hg and
a diastolic pressure less than 80 mm Hg, and
in patients with proteinuria, it must be
greater than 1000 mg/day BP<125/75. Some
studies demonstrated that angiotensin II–
receptor blockers may be more effective
than ACE inhibitors for decreasing
proteinuria and renoprotective effect in
micro or macro-albuminuric phases.6
Combination of angiotensin converting
inhibitors plus angiotensin receptor blockers
(dual system blocking) was shown more
effective than single agent therapy in some
studies.7,8 However, a large double-blinded
clinical trial was carried out on 1448 type-2
diabetic patients and losartan plus lisinopril
were prescribed to maximal reduction of
proteinuria. Unfortunately, this study was
stopped due to significant adverse effects of
drugs especially serious hyperkalemia and
acute renal failure.9
There are new treatment methods for DN
patients. For example, Aliskiren, a direct renin
inhibitor has the anti-proteinuric effect in
diabetic patients.10 So, Persson and colleagues
in a double-blinded clinical trial found that
combination of aliskiren and irbesartan had
more antiproteinuric effect than monotherapy
with another medication in type 2 diabetic
patients.11 The second antihypertensive agents
“nondihydropridin calcium channel blockers”
also have the renoprotective effect probably
due to decreasing hyperfiltration and
intraglomerular pressure.12
Third antiproteinuric agent is fibrate, as
in small clinical trial, fenofibrate was shown
to be effective in reducing proteinuria in
addition of lipid lowering property.13
Vitamin D is the fourth agent, since vitamin
D (VD) deficiency probably is a risk factor
of deterioration of diabetic nephropathy, so
in patients with VD deficiency, replacement
of oral VD was shown to be effective in
reduction of proteinuria.14,15 Fifth agent is
Allopurinol, as hyperuricemia is also
another potential risk factor of
cardiovascular and renal mortality; and in
comparison with the patients without
proteinuria, it has been seen that serum level
of uric acid may be greater in DN patients
with nephropathy. For example, in the study
of Momeni and colleagues, prescription of
allopurinol 100 mg/day was shown to be
effective in reducing proteinuria in type 2
diabetic patients.16 As, the sixth medication,
spironolactone was used in some studies for
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reduction of proteinuria in DN patients.17,18
Since aldosterone can exacerbate tissue
fibrosis especially in patients with heart
failure; so it can induce general renal vascular
inflammation and glomerulosclerosis probably
through profibrotic and proinflammatory
cytokines. Spironolactone has not a significant
role in declining the blood pressure; in
addition, it cannot reduce serum glucose.
However; it has probably renoprotective effect
due to its anti-inflammatory property. In
another study on type 2 diabetic patients, it
was found that spironolactone could reduce
proteinuria but hyperkalemia may occur.
However, combination of hydrochlorothiazide
and spironolactone has similar antiproteinuric
effect without the adverse effects of
hyperkalemia.17 The seventh new treatment
method could be prescription of
Thiazolidinediones such as Pioglitazone that
may have antiproteinuric effect due to an anti-
inflammatory mechanism. Moreover, it may
improve the insulin resistance, glycaemic
control and lipid profile. However, the studies
about the effect of thiazolidinediones mainly
were done in rats.19 The last new treatment
modality may be selective endothelin receptor
antagonists, due to the adverse effects of
Endothelin-1 on kidneys including
vasoconstriction, glomerulosclerosis, and
induction of cytokine expression.20 In a study
on 211 patients diabetic by de Zeeuw,
atrasentan (a selective endothelin receptor
antagonist), was tend to the reduction of
albuminuria and improvement of blood
pressure and lipid profile with manageable
fluid overload-related adverse effect in
patients receiving RAS inhibitors.21
CONCLUSION
Currently, the cornerstone of diabetic
nephropathy is prescription of angiotensin
receptor antagonists or angiotensin
converting enzyme inhibitors or
combination of two classes of drugs. For
increasing the antiproteinuric effect of
treatment or occurring the adverse effects of
these drugs, (especially hyperkalemia), other
agents such as Ca channel blockers, direct
renin inhibitors, thioglithazons, uric acid
lowering drugs or vitamin D may be added
or replaced. It seems that additional double
blind clinical trials with long follow-up are
needed for declaration of the exact role and
determination of long-time effects of these
new methods of treatment.
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